mycophenolate mofetil

Mycophenolate mofetil is an immunosuppressive prodrug of mycophenolic acid, classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). It selectively inhibits the de novo synthesis pathway of guanosine nucleotides, which is critical for the proliferation of T and B lymphocytes. By blocking this pathway, it suppresses immune responses and prevents organ rejection in transplant recipients. The drug is primarily used in combination with other immunosuppressants to prevent rejection following kidney, heart, or liver transplantation. It is also used off-label for various autoimmune diseases such as lupus nephritis and rheumatoid arthritis[1][3][4][5]. Developed to improve upon the gastrointestinal tolerability issues seen with earlier forms of mycophenolic acid, mycophenolate mofetil offers increased bioavailability and efficacy.

Brand names

CellCeptMyhibbinMyclausenMyfenax

Other names

mycophenolic acid morpholinoethyl esterMMF